CGC Genetics New Products: CGC Genetics' Diabetes/Obesity Mutation Panel Premium Portuguese genetic testing firm CGC Genetics recently launched a Diabetes/Obesity Mutation Panel that it claims can be used for preventive purposes. CGC Genetics Rolls out BeadXpress-based Test for Skeletal Dysplasia Premium CGC Genetics, a clinical genetics testing company, recently introduced a panel for skeletal dysplasias. The assay runs on Illumina's digital microbead-based BeadXpress system, and bolsters the Porto, Portugal-based company's menu of Array CGC tests. CGC Genetics Adopts Illumina BeadXpress for Clinical Genetic Testing Premium The Portugal-based testing company is one of a handful of firms to adopt the holographic microbead-based platform since the US Food and Drug Administration cleared the BeadXpress earlier this year. New Product Watch: Dec 7, 2010 Premium Exiqon's Mircury LNA MicroRNA Arrays, CGC Genetics' Prenatal Diagnostic Test New Product Watch: Oct 26, 2010 Premium CGC Genetics' Congenital Deafness Panel, EMD Millipore's CpGenome Turbo Kit Sep 7, 2010 New Product Watch: Sep 7, 2010 Premium Apr 5, 2010 CGC Genetics Opens US HQ in New Jersey Apr 6, 2009 CGC Genetics Gets California Clinical Lab License Breaking News Gastric Cancer Chemotherapy Response, Prognoses Predicted With Blood-Based Immune Proteomics International Commission to Expand Molecular Testing Access for Cancer Patients NYU Langone Perlmutter Cancer Center to Validate Biological Dynamics Pancreatic Cancer Test SomaLogic Expands Into Middle East With Proteomics Supply Deal for Group 42 Healthcare Arima Genomics to Offer NGS-Based Gene Fusion Test Through Protean BioDiagnostics CLIA Lab The Scan Drug Response Variants May Be Distinct in Somatic, Germline Samples Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline. Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine. Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures. Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.